Skip to main
MRNA

Moderna (MRNA) Stock Forecast & Price Target

Moderna (MRNA) Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 0%
Buy 9%
Hold 64%
Sell 27%
Strong Sell 0%

Bulls say

Moderna is projected to see significant growth in product sales, with estimates of $1.73 billion for 2025, increasing to $2.15 billion in 2026, reflecting the successful expansion of its mRNA platform into various therapeutic areas. The company's efforts to enhance its balance sheet through a $1.5 billion debt deal will provide greater flexibility to navigate uncertainties while capitalizing on future opportunities. Additionally, improvements in manufacturing efficiency may lead to a gross margin rebound from 30% in 2023 back to 50% by 2025, further underpinning the company’s robust financial outlook.

Bears say

Moderna's financial outlook reflects significant challenges, particularly with a steep decline in COVID vaccine sales, which are projected to fall from $18 billion in 2022 to $6.7 billion in 2023, while future revenue from COVID-related products appears increasingly uncertain due to waning vaccination rates and competitive pressures in the respiratory vaccine market. The company has also adjusted its long-term financial expectations downward, with projected annual revenue from COVID vaccines diminishing from $3.5 billion to $2.5 billion as the pandemic transitions to an endemic phase. Additionally, ongoing negotiations within the EU suggest that sales opportunities may be limited, compounding the negative outlook for Moderna's revenue growth potential across its broader pipeline.

Moderna (MRNA) has been analyzed by 11 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 9% recommend Buy, 64% suggest Holding, 27% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Moderna (MRNA) Forecast

Analysts have given Moderna (MRNA) a Hold based on their latest research and market trends.

According to 11 analysts, Moderna (MRNA) has a Hold consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.91, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.91, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Moderna (MRNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.